| Subject: | FDA Issues Public Health Advisory for Rituxan (Rituximab) |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Wed, 20 Dec 2006 - 12:00 am |
| The FDA and Genentech are informing healthcare professionals of important emerging safety information about Rituxan. Two patients died after being treated with Rituxan for systemic lupus erythematosus (SLE). The cause of death was a viral infection of the brain called progressive multifocal leukoencephalopathy (PML) that is caused by reactivated JC virus, which is present in about 80 percent of adults.
Rituxan is approved for the treatment of CD20-positive, B-cell, non Hodgkins lymphoma and... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
REFERENCES:
Policies / Forms / Additional Resources:
External Links:
|
|
StayAlert! provides immediate notification of regulatory body legislation impacting the healthcare industry, helping you to meet regulatory compliance. Subscribers are notified of any new or revised regulations, provided with a summary of the regulation, followed by an implementation action plan and/or policy. Designed as an e-mail "push" method for rapid customer notification of healthcare compliance issues, paired with interpretative analysis and practical application, the StayAlert!® Virtual Compliance Administrator™ saves you time and money. The StayAlert! system was designed by healthcare professionals actively working in the healthcare environment, who were faced with attempting to competently provide quality care and services while "doing more with less". StayAlert! provides the answer to efficiently performing a variety of required job components from one centralized virtual location. StayAlert! improves data sharing and communications, thus reducing cost, broadening access and providing a system of documentation and follow-up. |
|
